Annual Financials for Teva Pharmaceutical Industries Ltd. ADR
Fiscal year is January-December. All values ILS millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
80.52B | 65.69B | 60.12B | 57.29B | 51.19B | |
Sales Growth |
- | -18.42% | -8.48% | -4.70% | -10.65% | |
Cost of Goods Sold (COGS) incl. D&A |
42.34B | 35.86B | 33.32B | 30.72B | 27.08B | |
COGS excluding D&A |
34.87B | 29.24B | 27.18B | 25.37B | 22.78B | |
Depreciation & Amortization Expense |
7.47B | 6.62B | 6.14B | 5.35B | 4.3B | |
Depreciation |
2.27B | 2.43B | 2.17B | 1.85B | 1.71B | |
Amortization of Intangibles |
5.19B | 4.19B | 3.97B | 3.51B | 2.59B | |
COGS Growth |
- | -15.29% | -7.10% | -7.79% | -11.86% | |
Gross Income |
38.18B | 29.83B | 26.8B | 26.57B | 24.11B | |
Gross Income Growth |
- | -21.88% | -10.14% | -0.86% | -9.26% | |
Gross Profit Margin |
- | - | - | - | 47.10% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
23.83B | 19.51B | 17.16B | 16.05B | 14.2B | |
Research & Development |
6.4B | 4.36B | 3.6B | 3.43B | 3.12B | |
Other SG&A |
17.43B | 15.15B | 13.56B | 12.62B | 11.08B | |
SGA Growth |
- | -18.11% | -12.05% | -6.45% | -11.55% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
81.2B | 16.96B | 11.1B | 23.29B | 4.35B | |
EBIT after Unusual Expense |
(81.2B) | (16.96B) | (1.46B) | (12.78B) | 5.56B | |
Non Operating Income/Expense |
3.26B | 553.67M | 213.78M | 137.56M | (187.35M) | |
Non-Operating Interest Income |
302.15M | 140.22M | 146.08M | 82.54M | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
2.83B | 3.38B | 3.41B | 2.6B | 3.25B | |
Interest Expense Growth |
- | 19.38% | 0.90% | -23.85% | 25.15% | |
Gross Interest Expense |
2.83B | 3.38B | 3.41B | 2.6B | 3.25B | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(66.11B) | (9.33B) | (4.51B) | (15.15B) | 2.13B | |
Pretax Income Growth |
- | 85.88% | 51.71% | -236.18% | 114.03% | |
Pretax Margin |
- | - | - | - | 4.15% | NA |
Income Tax |
(6.95B) | (701.08M) | (990.52M) | (577.76M) | 681.56M | |
Income Tax - Current Domestic |
1.34B | 2.52B | 3.15B | 625.9M | 872.13M | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
(8.29B) | (3.22B) | (4.14B) | (1.2B) | (190.58M) | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
(10.79M) | (255.26M) | (46.32M) | 474.59M | 29.07M | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(59.17B) | (8.89B) | (3.56B) | (14.1B) | 1.47B | |
Minority Interest Expense |
(661.84M) | (1.16B) | (3.56M) | (378.29M) | 125.97M | |
Net Income |
(58.5B) | (7.73B) | (3.56B) | (13.72B) | 1.35B | |
Net Income Growth |
- | 86.79% | 53.95% | -285.50% | 109.82% | |
Net Margin Growth |
- | - | - | - | 2.63% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(58.5B) | (7.73B) | (3.56B) | (13.72B) | 1.35B | |
Preferred Dividends |
935.21M | 895.22M | - | - | - | |
Net Income Available to Common |
(59.44B) | (8.63B) | (3.56B) | (13.72B) | 1.35B | |
EPS (Basic) |
(58.50) | (8.45) | (3.26) | (12.53) | 1.22 | |
EPS (Basic) Growth |
- | 85.56% | 61.38% | -284.10% | 109.75% | |
Basic Shares Outstanding |
1.02B | 1.02B | 1.09B | 1.1B | 1.1B | |
EPS (Diluted) |
(58.50) | (8.45) | (3.26) | (12.53) | 1.22 | |
EPS (Diluted) Growth |
- | 85.56% | 61.38% | -284.10% | 109.71% | |
Diluted Shares Outstanding |
1.02B | 1.02B | 1.09B | 1.1B | 1.11B | |
EBITDA |
21.82B | 16.94B | 15.78B | 15.87B | 14.21B | |
EBITDA Growth |
- | -22.39% | -6.85% | 0.60% | -10.49% | |
EBITDA Margin |
- | - | - | - | 27.75% | NA |